Screener
Viridian Therapeutics, Inc. VRDN Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.
The source filing: Viridian Therapeutics, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:30 AM EST
- Fiscal year
- FY2025
- Accession
- 0001590750-26-000007
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Proceeds from the issuance of Series B convertible preferred stock in offerings | — | 25,001 | 76,192 |
| Payments of issuance costs associated with the sale of convertible preferred stock | — | (1,500) | (4,588) |
| Proceeds from the exercise of warrants | 1,618 | — | 1,881 |
| Proceeds from issuance of long-term debt, net | 28,875 | — | 15,000 |
| Payment of debt issuance costs | (478) | — | (514) |
| Proceeds from sale of future revenue | 55,000 | — | — |
| Payment of issuance costs associated with sale of future revenue | (4,981) | — | — |
| Proceeds from issuance of common stock upon exercise of stock options | 12,053 | 5,344 | 19,263 |
ITEM 16. FORM 10-K SUMMARY
FAQ
- What is Viridian Therapeutics, Inc.'s debt issuance proceeds?
- Viridian Therapeutics, Inc. (VRDN) reported debt issuance proceeds of $7.22M in Q4 2025.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Viridian Therapeutics, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude